Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral Rehydration Salts Powder (III) (also known as Oral Rehydration Salts (III)) is an approved oral pharmaceutical product developed and manufactured by Shandong Dyne Marine Organism Pharmaceutical, among other manufacturers. It is a low-osmolarity oral rehydration salts (ORS) formulation designed in accordance with the World Health Organization (WHO) and UNICEF recommendations. The formulation consists of a precise mixture of sodium chloride, anhydrous glucose, potassium chloride, and sodium citrate. It is indicated for the prevention and treatment of mild-to-moderate dehydration and electrolyte loss resulting from acute diarrhea, vomiting, or other fluid-depleting conditions, particularly in pediatric populations. The therapeutic efficacy of the formulation relies on the sodium-glucose cotransporter 1 (SGLT1) in the intestinal mucosa, where the active co-transport of sodium and glucose creates an osmotic gradient that drives the passive absorption of water and essential electrolytes back into the systemic circulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oral rehydration salts (III).